Filing Analysis
Delcath Systems, Inc. has amended and restated its Bylaws to include exclusive forum provisions for internal corporate claims and securities-related claims.
📋 Key Facts
- The Board of Directors approved the amendments on August 12, 2026.
- Amendments establish the Court of Chancery of the State of Delaware (or federal district court in Delaware) as the exclusive forum for internal corporate claims.
- Federal district courts of the United States are established as the exclusive forum for claims arising under the Securities Act of 1933.
- The changes were made upon recommendation from the Nominating and Corporate Governance Committee.
Delcath Systems, Inc. filed an 8-K to furnish its quarterly press release announcing financial results and business highlights for the quarter ended June 30, 2026.
📋 Key Facts
- Report date: August 6, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information provided in the press release is furnished, not filed, under Section 18 of the Exchange Act.
Delcath Systems, Inc. announced that its board of directors has authorized a new share repurchase program. The company intends to repurchase up to $25 million of its outstanding common stock, subject to market conditions.
📋 Key Facts
- Board authorization date: November 19, 2025
- Maximum repurchase amount: $25 million
- Security type: Common Stock
- Repurchase terms: Subject to market conditions and time-bound discretion
Delcath Systems, Inc. filed an 8-K to furnish a press release announcing its financial results and business highlights for the quarter ended September 30, 2025.
📋 Key Facts
- Report date: November 4, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information in the press release is furnished but not 'filed' for purposes of Section 18 liability.
Delcath Systems, Inc. announced positive clinical trial results from the CHOPIN Trial and provided preliminary Q3 2025 financial results showing profitability and strong revenue growth.
🚩 Red Flags
- Financial results are preliminary and unaudited; subject to change upon final review.
📋 Key Facts
- CHOPIN Trial: Combination therapy (PHP + ICI) showed a one-year progression-free survival of 54.7% vs. 15.8% for PHP alone (p<0.001).
- CHOPIN Trial: Median overall survival was 23.1 months for the combination group vs. 19.6 months for the PHP group.
- Q3 2025 Preliminary Revenue: Approximately $20.5 million total, driven largely by HEPZATO KIT ($19.2 million).
- Q3 2025 Profitability: Reported net income of $0.8 million and positive adjusted EBITDA of $5.3 million.
- Cash Position: As of Sept 30, 2025, the company held ~$88.9 million in cash/equivalents with no debt.
- Gross Margins: Expected to be 87% for the quarter.
Delcath Systems, Inc. has amended and restated its Bylaws effective August 12, 2025. The changes focus on stockholder nomination procedures, officer election duties, indemnification rights, and administrative modernization.
📋 Key Facts
- The Board of Directors approved the Amended and Restated Bylaws on August 12, 2025.
- Updates include clarified procedural requirements for stockholder nominations and proposals.
- Provisions regarding the election and duties of officers and the Chairperson were updated.
- Bylaws now include updated descriptions of indemnification rights for directors and officers.
- The amendments incorporate modernizing changes such as updates to notice periods and remote communications.
Delcath Systems, Inc. filed an 8-K to furnish its quarterly press release for the period ended June 30, 2025. The filing serves as a formal announcement of financial results and business highlights.
📋 Key Facts
- Report date: August 6, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes Exhibit 99.1 containing the press release with financial results and business highlights.
- Signed by Sandra Pennell, Chief Financial Officer.
Delcath Systems, Inc. announced plans to enter into a National Medicaid Drug Rebate Agreement (NDRA) with CMS, expected to take effect in Q3 2025. The company also issued its full-year 2025 guidance via press release.
🚩 Red Flags
- Forward-looking statements regarding the NDRA include uncertainty regarding the company's ability to successfully enter the agreement and its potential impact on operations.
📋 Key Facts
- Plans to enter into a National Medicaid Drug Rebate Agreement (NDRA) with the Centers for Medicare & Medicaid Services.
- The NDRA is expected to take effect at the beginning of the third quarter of 2025.
- Issued full-year 2025 guidance via press release on May 22, 2025.
Delcath Systems, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on May 15, 2025. The meeting included the election of two directors and approval of amendments to equity incentive plans.
📋 Key Facts
- Annual Meeting held on May 15, 2025; 67.1% of eligible shares (22,755,045) were represented.
- Stockholders approved increasing the 2020 Omnibus Equity Incentive Plan by 2,200,000 shares.
- Stockholders approved increasing the 2021 Employee Stock Purchase Plan by 300,000 shares.
- Gerard Michel and Gilad Aharon were elected to Class I directors until the 2028 Annual Meeting.
- CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
Delcath Systems, Inc. filed an 8-K to announce its quarterly financial results and business highlights for the period ending March 31, 2025.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results and business highlights.
- Information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 liability.
Delcath Systems, Inc. announced the resignation of Marcum LLP as its independent registered accounting firm and the immediate appointment of CBIZ CPAs P.C. for the fiscal year ending December 31, 2025.
🚩 Red Flags
- Auditor change in a micro-cap context often warrants scrutiny for potential underlying issues despite management's claims of 'no disagreements'.
- The 2023 fiscal year report included an explanatory paragraph relating to substantial doubt about the Company’s ability to continue as a going concern.
📋 Key Facts
- Marcum LLP resigned as the Company's independent auditor on March 18, 2025.
- CBIZ CPAs P.C. was engaged as the new independent registered public accounting firm, effective immediately.
- The resignation follows Marcum's acquisition of the attest business of CBIZ CPAs on November 1, 2024.
- The Company stated there were no disagreements with Marcum regarding accounting principles or auditing procedures prior to the resignation.
Delcath Systems, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024. The filing serves as a formal announcement of the release of these earnings via press release.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2024.
- Announcement date: March 6, 2025.
- The filing includes an exhibit (99.1) containing the earnings press release.
Delcath Systems, Inc. issued a press release announcing preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. The company also updated its corporate presentation.
🚩 Red Flags
- Preliminary results are unaudited and subject to audit adjustments.
📋 Key Facts
- Preliminary Q4/Full Year 2024 revenue expected at $15.1M and $37.2M respectively.
- HEPZATO KIT™ expected to contribute $13.7M in Q4 and $32.3M for the full year.
- CHEMOSAT® expected to contribute $1.4M in Q4 and $4.9M for the full year.
- Expected gross margins are in the 80%-85% range.
- As of Dec 31, 2024, company held $53.2 million in cash, cash equivalents, and short-term investments with no debt.
- Reported 14 active sites utilizing HEPZATO KIT as of year-end 2024.
- Approximately 36.2 million shares of common stock were issued and outstanding.
Delcath Systems, Inc. announced the exercise of existing warrants resulting in approximately $16.3 million in gross proceeds. The transaction involved a combination of common stock and pre-funded warrants to prevent institutional holders from exceeding beneficial ownership thresholds.
🚩 Red Flags
- Use of 'Pre-Funded Warrants' is often used by micro-cap companies to issue equity to institutional investors without triggering immediate large-scale ownership thresholds, which can lead to significant future dilution.
- The issuance of pre-funded warrants at $0.01 exercise price represents a highly dilutive instrument for existing shareholders.
📋 Key Facts
- Company received aggregate gross proceeds of approximately $16.3 million on December 24, 2024.
- 1,746,424 Existing Warrants were exercised.
- Exercise resulted in the issuance of 1,045,157 shares of Common Stock and 603,954 Pre-Funded Warrants.
- Pre-Funded Warrants have an exercise price of $0.01 per underlying share and are immediately exercisable.
- Warrant amendments were implemented to allow holders to receive pre-funded warrants instead of common stock if exercising would exceed a 9.99% beneficial ownership threshold.
Delcath Systems, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended September 30, 2024. This is a routine regulatory filing used to disclose financial results and business highlights.
📋 Key Facts
- Filed on November 8, 2024
- Reports results of operations and financial condition for the quarter ended September 30, 2024
- Includes a press release as Exhibit 99.1
Delcath Systems announced preliminary Q3 2024 revenue of $11.2 million, driven by $10.0 million from HEPZATO KIT commercialization. This revenue milestone triggers the exercise of Tranche B warrants from a March 2023 PIPE, potentially resulting in the issuance of shares for up to $25 million.
🚩 Red Flags
- Significant potential dilution: The triggering of Tranche B warrants allows holders to purchase shares for up to $25 million, which may impact existing shareholders.
- Uncertainty in financial reporting: Management noted that final Q3 2024 results are not yet finalized and could differ from estimates.
📋 Key Facts
- Preliminary Q3 2024 revenue estimate: ~$11.2 million.
- HEPZATO KIT US commercialization revenue component: $10.0 million.
- Tranche B warrants from March 29, 2023 PIPE are now triggered for exercise.
- Warrant holders have 21 days to exercise at an effective price of $6.00 per share.
- Total aggregate exercise price for Tranche B warrants is approximately $25 million.
Delcath Systems, Inc. issued an 8-K to furnish a press release regarding positive results from an independent study on liver-directed therapy for uveal melanoma patients.
📋 Key Facts
- The filing pertains to positive results from an independent study.
- The study focused on liver-directed therapy for uveal melanoma patients.
- Results were announced via press release on August 28, 2024.
- Information is furnished under Item 7.01 (Regulation FD Disclosure) and not considered 'filed' for liability purposes.
Delcath Systems, Inc. issued two press releases regarding positive results from independent studies involving hepatic chemosaturation and hepatic perfusion for specific tumor treatments.
📋 Key Facts
- August 26, 2024: Announced promising results from an independent study on repeated hepatic chemosaturation for liver tumors (Exhibit 99.1).
- August 27, 2024: Announced positive outcomes from an independent study on hepatic perfusion for uveal melanoma patients (Exhibit 99.2).
Delcath Systems, Inc. filed an 8-K to furnish its quarterly press release announcing financial results and business highlights for the quarter ended June 30, 2024.
📋 Key Facts
- Report date: August 5, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing is a standard announcement of quarterly results via press release (Item 2.02).
Delcath Systems, Inc. entered into new employment agreements for several key executives, including the CEO, SVP of Finance, and General Manager of Interventional Oncology, effective July 2024.
🚩 Red Flags
- Multiple executive employment updates in a single filing can sometimes precede management turnover or restructuring, though not explicitly stated here.
📋 Key Facts
- On July 16, 2024, Delcath entered a new CEO Employment Agreement with Gerard Michel, replacing his previous agreement from August 31, 2020.
- CEO Gerard Michel's severance includes 15 months of base salary and COBRA reimbursement if terminated without cause or resigning for good reason; this increases to 18 months in the event of a change in control.
- On July 17, 2024, an employment agreement was entered with Sandra Pennell (SVP Finance) providing 12 months of severance/COBRA coverage.
- A new agreement was also executed for Kevin Muir (GM Oncology) on July 17, 2024, with similar 12-month severance terms.
- All agreements include customary non-disparagement, non-solicitation, and confidentiality provisions.
Delcath Systems, Inc. has successfully regained compliance with Nasdaq's audit committee composition requirements. This follows a previous non-compliance notice issued on May 29, 2024.
🚩 Red Flags
- Previous delisting risk/non-compliance notice (May 29, 2024) indicates historical governance issues.
📋 Key Facts
- On July 8, 2024, Nasdaq informed the Company it had regained compliance with Listing Rule 5605 regarding audit committee composition.
- The company was previously non-compliant due to having fewer than three 'independent directors' on its Audit Committee.
- Compliance was achieved via the appointment of Dr. Bridget Martell to the Audit Committee on July 2, 2024.
Delcath Systems, Inc. reported that it is no longer in compliance with Nasdaq Listing Rule 5605(c)(2) due to insufficient Audit Committee composition following the retirement of Roger Stoll. The company has a cure period to regain compliance by May 23, 2025.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq Listing Rule 5605(c)(2) regarding Audit Committee composition.
- Reduction in board oversight capacity due to the departure of a key director from the Audit Committee.
📋 Key Facts
- Nasdaq confirmed non-compliance on May 29, 2024, regarding Audit Committee composition requirements.
- The Audit Committee currently consists of only two qualified directors; Nasdaq requires at least three.
- Roger Stoll's retirement from the Board and Audit Committee became effective following the May 23, 2024 Annual Meeting.
- Stockholders approved an amendment to increase the 2020 Omnibus Equity Incentive Plan by 2,000,000 shares.
- Bridget Martell, M.A. M.D., was appointed as a Class III Director on May 23, 2024.
- Stockholders ratified Marcum, LLP as the independent registered public accounting firm for fiscal year 2024.
Delcath Systems, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended March 31, 2024. The filing serves as a formal announcement of financial results and business highlights.
📋 Key Facts
- Report date: May 14, 2024
- Reporting period: Quarter ended March 31, 2024
- The company issued a press release (Exhibit 99.1) containing financial results and business highlights.
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
Delcath Systems, Inc. entered into a fifth amendment to its License, Supply and Contract Manufacturing Agreement with Synerx Pharma, LLC and Mylan Teoranta regarding the supply of melphalan hydrochloride.
🚩 Red Flags
- Increased inventory/supply chain commitment: The 210-day advance purchase order requirement may impact working capital management.
📋 Key Facts
- Amendment effective date: May 1, 2024
- Agreement term extended to December 31, 2028
- Requires Delcath to place purchase orders at least 210 days before delivery
- Modifies the price per vial for the Product
- Includes annual price increases tied to the Producer Price Index (PPI) for pharmaceutical preparation and manufacturing
Delcath Systems, Inc. issued an 8-K to furnish its fourth quarter and full year 2023 financial results and a general business update via press release.
📋 Key Facts
- Report date: March 26, 2024
- Reporting period: Q4 and Full Year 2023
- The filing includes an earnings press release (Exhibit 99.1)
- Information is furnished under Item 2.02 rather than filed for liability purposes under Section 18.
Delcath Systems, Inc. completed a private placement of common stock and pre-funded warrants on March 19, 2024, raising approximately $7 million in gross proceeds. The funds are intended for working capital and general corporate purposes.
🚩 Red Flags
- Issuance of pre-funded warrants can lead to significant future dilution as they are almost equivalent to common stock.
- The Registration Rights Agreement includes liquidated damages (1.0% per holder) if the company fails to meet registration deadlines, creating potential contingent liabilities.
📋 Key Facts
- Private placement closed on March 19, 2024.
- Issued 876,627 shares of common stock at $3.72 per share.
- Issued 1,008,102 pre-funded warrants at $3.71 per warrant (exercise price of $0.01).
- Total gross proceeds: approximately $7 million.
- Registration Rights Agreement requires a registration statement to be filed by May 13, 2024.
Delcath Systems, Inc. announced the appointment of Martha S. Rook, Ph.D., as Chief Operating Officer, effective March 18, 2024. This follows the planned retirement of the previous COO, John Purpura, who will transition into a six-month consulting role.
🚩 Red Flags
- The transition of a C-suite officer (COO) can sometimes signal internal friction, though here it is framed as a planned retirement.
📋 Key Facts
- Martha S. Rook, Ph.D., appointed as Chief Operating Officer (COO) effective March 18, 2024.
- John Purpura is retiring from the COO role but will serve as a consultant for six months.
- Ms. Rook's compensation includes a $425,000 annual base salary and an inducement equity grant of 125,000 stock options vesting over 36 months.
- Mr. Purpura's consulting agreement involves the vesting of 91,596 stock options through September 19, 2025.
Delcath Systems, Inc. announced the planned retirement of its Chief Operating Officer, John Purpura, and the intention of long-time board member Roger Stoll to retire from the Board at the 2024 Annual Meeting.
🚩 Red Flags
- Departure of a key C-suite executive (COO) during a critical commercial launch phase.
📋 Key Facts
- COO John Purpura notified the company on February 12, 2024, of his intent to retire.
- The Company has identified a preferred candidate for the COO position and is in active discussions.
- John Purpura will remain until a successor is named and will provide consulting services post-departure.
- Board member Roger Stoll notified the company on February 9, 2024, of his intent to retire and not stand for re-election at the 2024 Annual Meeting.
- Mr. Stoll has served on the Board for over fourteen years.
- The departures are not due to any disagreements with Company operations, policies, or practices.
Delcath Systems, Inc. announced that CMS has established a permanent, product-specific J-code (J9248) for its product HEPZATO. This code is scheduled to become effective on April 1, 2024.
📋 Key Facts
- CMS established a permanent and product-specific J-code (J9248) for HEPZATO.
- The new J-code becomes effective on April 1, 2024.
- Announcement made via press release on January 31, 2024.
Delcath Systems, Inc. filed an 8-K to furnish an updated corporate presentation dated January 5, 2024. This filing is for informational purposes under Regulation FD and does not contain material non-public information or financial changes.
📋 Key Facts
- The company released an updated corporate presentation on January 5, 2024.
- The presentation is intended for use in conferences and investor meetings.
- The filing was signed by CEO Gerard Michel on January 8, 2024.